Dr. Reddy's Laboratories has moved sharply lower in the session following its Q1 print, and the positioning story that dominated the pre-earnings setup is now being tested by hard price action.
The market's response has been unambiguous. The ADR fell 9.4% on Wednesday alone and is down 10.9% on the week, extending a one-month decline that now reaches 14.4% to $11.38. As previously noted in the July 22 trader note, the week had already delivered early pressure — but the session following the actual earnings release has accelerated the move considerably. This is company-specific pain: the broader Indian pharma sector has not seen comparable selling, a pattern consistent with the peer divergence flagged in earlier coverage.
The borrow market has tightened again in response. Availability dropped to 45% on July 21 — down sharply from 65% the prior session and well below the mid-60s range that prevailed through much of the past week. That tightening reverses some of the loosening that had followed the late-June squeeze, when availability had collapsed to just 5.3% at its most extreme. Cost to borrow has eased from those highs to 1.44%, but the renewed availability pressure suggests fresh demand for short exposure is building rather than fading. Short interest itself has drifted slightly lower — around 21.4 million shares, down about 2.4% on the week — but the direction of the borrow market tells a less comfortable story for bulls.
Options positioning had flagged caution ahead of the print. The put/call ratio ran at 0.55 into the report, above its 20-day average of 0.42 and roughly 1.2 standard deviations elevated — not an extreme reading, but consistent with hedging demand that has now proved well-placed. Analyst data is too stale to be actionable here: the consensus as-of date is August 2023, and the most recent price target changes (HSBC's June 2025 upgrade to $16.90, Barclays maintaining Overweight) predate the current price level by enough that the gap makes direct comparison unreliable.
The earnings report has now printed — the question the market is answering is whether the 14% one-month decline has already discounted the fundamental deterioration, or whether the Q1 numbers reveal a deeper problem with margins and generic competition that warrants another leg lower.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
